MLRT - MetAlert Inc. (MLRT) Developing Innovative Location-Sensitive Health Monitoring and Supervision Products as It Targets Market Leadership in Telehealth Space
- MetAlert is a pioneer in location-sensitive health monitoring devices and wearable technology products targeting the Alzheimer’s, Dementia, and Autism (“ADA”) market
- The company is looking to provide cutting-edge telehealth technologies and is continuously working to roll out improved and more innovative products for its users
- Its SmartSole(R) product facilitates discreet tracking and remote monitoring of ADA patients
- The company has also launched SmartSole plus(R), which adds Bluetooth and Wi-Fi capabilities for better tracking
- MetAlert also distributes RoomMate, a wall-mounted 3D infrared supervision product that enables caregivers to look after patients without intruding on their personal space
The policy changes spearheaded by the US government at the height of the COVID-19 pandemic boosted telehealth, including telemedicine. As a result, by April 2020, telehealth services constituted 32% of Medicare claims, up from less than 1% before the pandemic, and by July 2021, the figure had plateaued to between 13% and 17% (https://ibn.fm/QtTZL). Against this backdrop, a recent article (https://ibn.fm/9deW5) in Equities asks: “But will its momentum continue now that the pandemic has lost its urgency?”
While industry forecasts project that the telehealth space will expand at CAGRs ranging from 19% and 24% to as high as 32%, the author of the article is quick to point out that the adoption of new technologies in the...
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at http://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.